JP2022513586A5 - - Google Patents

Info

Publication number
JP2022513586A5
JP2022513586A5 JP2021523759A JP2021523759A JP2022513586A5 JP 2022513586 A5 JP2022513586 A5 JP 2022513586A5 JP 2021523759 A JP2021523759 A JP 2021523759A JP 2021523759 A JP2021523759 A JP 2021523759A JP 2022513586 A5 JP2022513586 A5 JP 2022513586A5
Authority
JP
Japan
Prior art keywords
population
cells
cancer
genetically engineered
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523759A
Other languages
English (en)
Japanese (ja)
Other versions
JP7471289B2 (ja
JP2022513586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059586 external-priority patent/WO2020095249A1/en
Publication of JP2022513586A publication Critical patent/JP2022513586A/ja
Publication of JP2022513586A5 publication Critical patent/JP2022513586A5/ja
Application granted granted Critical
Publication of JP7471289B2 publication Critical patent/JP7471289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523759A 2018-11-07 2019-11-07 抗liv1免疫細胞癌療法 Active JP7471289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756723P 2018-11-07 2018-11-07
US62/756,723 2018-11-07
PCT/IB2019/059586 WO2020095249A1 (en) 2018-11-07 2019-11-07 Anti-liv1 immune cell cancer therapy

Publications (3)

Publication Number Publication Date
JP2022513586A JP2022513586A (ja) 2022-02-09
JP2022513586A5 true JP2022513586A5 (cg-RX-API-DMAC7.html) 2022-11-15
JP7471289B2 JP7471289B2 (ja) 2024-04-19

Family

ID=68582073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523759A Active JP7471289B2 (ja) 2018-11-07 2019-11-07 抗liv1免疫細胞癌療法

Country Status (16)

Country Link
US (2) US12304968B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877419A1 (cg-RX-API-DMAC7.html)
JP (1) JP7471289B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210089707A (cg-RX-API-DMAC7.html)
CN (1) CN113015750A (cg-RX-API-DMAC7.html)
AU (1) AU2019376903A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008082A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118824A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006493A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191257A1 (cg-RX-API-DMAC7.html)
IL (1) IL282531A (cg-RX-API-DMAC7.html)
MX (1) MX2021005395A (cg-RX-API-DMAC7.html)
PH (1) PH12021551036A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104523PA (cg-RX-API-DMAC7.html)
WO (1) WO2020095249A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102740B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
ES2836743T3 (es) * 2014-06-02 2021-06-28 Us Health Receptores de antígeno quiméricos que seleccionan como diana CD-19
EA201891968A1 (ru) 2016-03-15 2019-02-28 Сиэтл Дженетикс, Инк. Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
BR112022012725A2 (pt) * 2019-12-24 2022-11-16 Jjp Biologics Sp Z O O Anticorpos hvem (tnfrsf14) anti-humanos e usos dos mesmos
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
IL322565A (en) 2023-02-07 2025-10-01 Lanova Medicines Ltd Antibodies targeting liv-1 and their uses
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
WO2025162207A1 (zh) * 2024-01-31 2025-08-07 上海复宏汉霖生物技术股份有限公司 抗liv1抗体及使用方法
WO2026057074A1 (zh) * 2024-09-14 2026-03-19 杭州博之锐生物制药有限公司 抗liv-1抗体-药物偶联物的组合疗法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
PT3156420T (pt) * 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
RU2752933C2 (ru) * 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
US11352631B2 (en) * 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
EA201891968A1 (ru) 2016-03-15 2019-02-28 Сиэтл Дженетикс, Инк. Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
JP7236380B2 (ja) * 2016-10-19 2023-03-09 セレクティス 治療に適したtalエフェクターヌクレアーゼ(talen)改変同種異系細胞
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法

Similar Documents

Publication Publication Date Title
JP2022509017A5 (cg-RX-API-DMAC7.html)
JP2024097924A5 (cg-RX-API-DMAC7.html)
JP2022512882A5 (cg-RX-API-DMAC7.html)
JP2021522820A5 (cg-RX-API-DMAC7.html)
JP6664528B2 (ja) Cld18a2標的免疫エフェクター細胞及びその調製方法と使用
IL278348B1 (en) Methods and compositions for treating cancer
CA2951355C (en) Car-expressing nk-92 cells as cell therapeutic agents
US10604740B2 (en) Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
JP2019532625A5 (cg-RX-API-DMAC7.html)
JP7471289B2 (ja) 抗liv1免疫細胞癌療法
JP2020519641A5 (cg-RX-API-DMAC7.html)
JP2019531056A5 (cg-RX-API-DMAC7.html)
US20250074965A1 (en) Anti-ptk7 immune cell cancer therapy
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
ES2871400T3 (es) Células inmunitarias deficientes en SUV39H1
JP2018522072A5 (cg-RX-API-DMAC7.html)
JP2021506243A5 (cg-RX-API-DMAC7.html)
HRP20240926T1 (hr) Claudin-6-specifični imunoreceptori i epitopi t stanica
JP2019525771A5 (cg-RX-API-DMAC7.html)
JP2017537620A5 (cg-RX-API-DMAC7.html)
JP2011157397A5 (cg-RX-API-DMAC7.html)
JP2016508725A5 (cg-RX-API-DMAC7.html)
Lee et al. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models
Gacerez et al. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression
JP2021534784A5 (cg-RX-API-DMAC7.html)